Row
M
MNPRAI Stock Diagnostic Report
Monopar cut to Neutral at Cantor on valuation
Cantor Fitzgerald has downgraded its investment rating on Monopar Therapeutics (MNPR) due to valuation concerns.
View Source Article ↗AI CATALYST SCORE40 / 100Score computed by Sentinel V12
REFERENCE PRICENot measuredReference entry price at analysis time
+ANALYSIS HISTORY
MNPR Analysis History (Last 30 Days)